Related Experiment Video
Updated: Oct 24, 2025

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
SUMOylation as a Therapeutic Target for Myocardial Infarction
Wei Zhao1,2, Xiuying Zhang1, Jianhui Rong1,3
1Li Ka Shing Faculty of Medicine, School of Chinese Medicine, University of Hong Kong, Hong Kong, China.
Abstract:
Myocardial infarction is a prevalent and life-threatening cardiovascular disease. The main goal of existing interventional therapies is to restore coronary reperfusion while few are designed to ameliorate the pathology of heart diseases via targeting the post-translational modifications of those critical proteins. Small ubiquitin-like modifier (SUMO) proteins are recently discovered to form a new type of protein post-translational modifications (PTM), known as SUMOylation. SUMOylation and deSUMOylation are dynamically balanced in the maintenance of various biological processes including cell division, DNA repair, epigenetic transcriptional regulation, and cellular metabolism. Importantly, SUMOylation plays a critical role in the regulation of cardiac functions and the pathology of cardiovascular diseases, especially in heart failure and myocardial infarction. This review summarizes the current understanding on the effects of SUMOylation and SUMOylated proteins in the pathophysiology of myocardial infarction and identifies the potential treatments against myocardial injury via targeting SUMO. Ultimately, this review recommends SUMOylation as a key therapeutic target for treating cardiovascular diseases.
Related Concept Videos
Myocarditis III: Medical Management
Coronary Artery Disease II: Pathophysiology
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Myocarditis I: Introduction
Acute Coronary Syndrome IV: Interprofessional Care
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

